- Press Releases archive
- < Recipharm to expand lyophilization capacity with €32 million investment in Germany
Recipharm to expand lyophilization capacity with €32 million investment in Germany
08 October 2013
Construction of new production building with large scale freeze drying capability sets the company on a course to expand business from both new and existing customers
8th October 2013 - Recipharm has today announced an investment of €32 million in its Wasserburg site located near Munich. The capital will be used to create a new building that will house a fourth production area adding to the three already in operation. This development will significantly increase the company’s lyophilization capacity and will result in a brand new state of the art facility equipped with the latest automatic loading and unloading technology. The building will also have the flexibility to accommodate further production lines. The number of employees will be increased from the current 282 to 320 and the new area is expected to be operational in 2016.
The Wasserburg facility has a long history of producing products in vials and ampoules for large, medium and small pharmaceutical companies and was established almost 40 years ago. It has emerged as a world leading specialist in aseptic filling and lyophilization of injectable drugs supplying Europe, the USA, Brazil and Asia Pacific.
Armin Dallüge, General Manager of Recipharm in Wasserburg said “We are absolutely delighted with this decision to significantly expand our facility. We have been operating at full capacity for several years now and we see this investment as vital to maintain and increase our leadership in this field. Demand for lyophilization is expected to increase in the coming years and we intend to be at the forefront of servicing this”.
Thomas Eldered, CEO of Recipharm AB, commented “Lyophilization is a fast growing technology which we believe will become even more important. Recipharm is one of the few Contract Development and Manufacturing Organisations with the capability to make such a significant commitment to this dose form and our financial stability sets us apart from our competitors. Given the excellent track record of Wasserburg and in particular the highly skilled workforce, we are very confident that this investment will help us to consolidate our position as one of the world’s leading CDMOs”.
Notes to editors
Recipharm AB is a leading contract development and manufacturing organisation (CDMO) based in Sweden employing some 1600 employees. The Company operates development and manufacturing facilities in Sweden, France, the UK, Germany and Spain and is headquartered near Stockholm. Recipharm supplies the global pharmaceuticals market with hundreds of different products in multiple dosage forms that include solid dose, semi solids, steriles (liquids and freeze dried), beta-lactams, hormones and dry powder inhalers, oral liquids and granulates.
For more information visit www.recipharm.com.